Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial.
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: For patients in intensive care units, sepsis is a common and potentially deadly complication and prompt initiation of appropriate antimicrobial therapy improves prognosis. The objective of this trial was to determine whether a strategy of antimicrobial spectrum escalation, guided by daily measurements of the biomarker procalcitonin, could reduce the time to appropriate therapy, thus improving survival. DESIGN: Randomized controlled open-label trial. SETTING: Nine multidisciplinary intensive care units across Denmark. PATIENTS: A total of 1,200 critically ill patients were included after meeting the following eligibility requirements: expected intensive care unit stay of ≥ 24 hrs, nonpregnant, judged to not be harmed by blood sampling, bilirubin <40 mg/dL, and triglycerides <1000 mg/dL (not suspensive). INTERVENTIONS: : Patients were randomized either to the "standard-of-care-only arm," receiving treatment according to the current international guidelines and blinded to procalcitonin levels, or to the "procalcitonin arm," in which current guidelines were supplemented with a drug-escalation algorithm and intensified diagnostics based on daily procalcitonin measurements. MEASUREMENTS AND MAIN RESULTS: The primary end point was death from any cause at day 28; this occurred for 31.5% (190 of 604) patients in the procalcitonin arm and for 32.0% (191 of 596) patients in the standard-of-care-only arm (absolute risk reduction, 0.6%; 95% confidence interval [CI] -4.7% to 5.9%). Length of stay in the intensive care unit was increased by one day (p = .004) in the procalcitonin arm, the rate of mechanical ventilation per day in the intensive care unit increased 4.9% (95% CI, 3.0-6.7%), and the relative risk of days with estimated glomerular filtration rate <60 mL/min/1.73 m was 1.21 (95% CI, 1.15-1.27). CONCLUSIONS: Procalcitonin-guided antimicrobial escalation in the intensive care unit did not improve survival and did lead to organ-related harm and prolonged admission to the intensive care unit. The procalcitonin strategy like the one used in this trial cannot be recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“length of ICU stays (MD 0.19 days; 95% CI −0.98 to 1.36)”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [129]
In the citing paper
“A meta-analysis of the three trials (n = 1769 ICU patients) found no difference in short-term mortality (RR 0.99; 95% CI 0.86–1.15)”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [129]
In the citing paper
“or length of hospitalisation (MD 7.00 days; 95% CI −26.24 to 12.24).”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [129]
In the citing paper
“Long-term mortality, readmission rates and hospital-free days were not reported in any of the trials, and no relevant studies on the costs associated with use of procalcitonin were found.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [129]
Citations
Cites
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Sepsis in European intensive care units: Results of the SOAP study*
Vincent, J.-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le Gall, J.-R., & Payen, D. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000194725.48928.3a · Cited by 2,836
High serum procalcitonin concentrations in patients with sepsis and infection
Assicot, M., Bohuon, C., Gendrel, D., Raymond, J., Carsin, H., & Guilbaud, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90277-n · Cited by 2,197
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Clinical features and prognostic factors in adults with bacterial meningitis
van de Beek, D., de Gans, J., Spanjaard, L., Weisfelt, M., Reitsma, J. B., & Vermeulen, M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040845 · Cited by 1,639
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Russell, J. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra043632 · Cited by 1,048
SINGH, N., ROGERS, P., ATWOOD, C. W., WAGENER, M. M., & YU, V. L. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.2.9909095 · Cited by 1,032
Schuetz, P., Christ-Crain, M., Thomann, R., Falconnier, C., Wolbers, M., Widmer, I., Neidert, S., Fricker, T., Blum, C., Schild, U., et al. (2009) · JAMA · doi:10.1001/jama.2009.1297 · Cited by 959
HARBARTH, S., HOLECKOVA, K., FROIDEVAUX, C., PITTET, D., RICOU, B., GRAU, G. E., VADAS, L., PUGIN, J., & the Geneva Sepsis Network (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.3.2009052 · Cited by 898
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
Uzzan, B., Cohen, R., Nicolas, P., Cucherat, M., & Perret, G.-Y. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000226413.54364.36 · Cited by 738
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients
Nobre, V., Harbarth, S., Graf, J.-D., Rohner, P., & Pugin, J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1238oc · Cited by 605
Becker, K. L., Nylén, E. S., White, J. C., Müller, B., & Snider, R. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021444 · Cited by 578
Castelli, G. P., Pognani, C., Meisner, M., Stuani, A., Bellomi, D., & Sgarbi, L. (2004) · Critical Care · doi:10.1186/cc2877 · Cited by 417
Procalcitonin increase in early identification of critically ill patients at high risk of mortality*
Jensen, J. U., Heslet, L., Jensen, T. H., Espersen, K., Steffensen, P., & Tvede, M. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000239116.01855.61 · Cited by 380
Self-citationDefinitions for sepsis and organ failure
Bone, R. C. (1992) · Critical Care Medicine · doi:10.1097/00003246-199206000-00002 · Cited by 360
Procalcitonin Kinetics as a Prognostic Marker of Ventilator-associated Pneumonia
Luyt, C.-E., Guérin, V., Combes, A., Trouillet, J.-L., Ayed, S. B., Bernard, M., Gibert, C., & Chastre, J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-746oc · Cited by 288
Vander Stichele, R. H., Elseviers, M. M., Ferech, M., Blot, S., & Goossens, H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl147 · Cited by 197
Martin, C. M., Priestap, F., Fisher, H., Fowler, R. A., Heyland, D. K., Keenan, S. P., Longo, C. J., Morrison, T., Bentley, D., & Antman, N. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819285f0 · Cited by 189
Markers of treatment failure in hospitalised community acquired pneumonia
Menendez, R., Cavalcanti, M., Reyes, S., Mensa, J., Martinez, R., Marcos, M. A., Filella, X., Niederman, M., & Torres, A. (2008) · Thorax · doi:10.1136/thx.2007.086785 · Cited by 184
Meisner, M., Lohs, T., Huettemann, E., Schmidt, J., Hueller, M., & Reinhart, K. (2001) · European Journal of Anaesthesiology · doi:10.1046/j.0265-0215.2000.00783.x · Cited by 163
Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia
Luyt, C.-E., Combes, A., Reynaud, C., Hekimian, G., Nieszkowska, A., Tonnellier, M., Aubry, A., Trouillet, J.-L., Bernard, M., & Chastre, J. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1112-x · Cited by 161
The natural elimination rate of procalcitonin in patients with normal and impaired renal function
Meisner, M., Schmidt, J. L., Hüttner, H., & Tschaikowsky, K. (2000) · Intensive Care Medicine · doi:10.1007/bf02900740 · Cited by 132
Biomarkers: Diagnosis and Risk Assessment in Sepsis
Ventetuolo, C. E., & Levy, M. M. (2008) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2008.07.001 · Cited by 116
Meisner, M., Lohs, T., Huettemann, E., et al. (2001) · European Journal of Anaesthesiology · doi:10.1097/00003643-200102000-00004 · Cited by 102
Dahaba, A. A., Rehak, P., & List, W. F. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1664-8 · Cited by 97
The natural elimination rate of procalcitonin in patients with normal and impaired renal function
Meisner, M., Schmidt, J. L., Hüttner, H., et al. (2000) · Intensive Care Medicine · doi:10.1007/s001340051146 · Cited by 87
Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System
Steinbach, G., Rau, B., Debard, A., Javourez, J.-F., Bienvenu, J., Ponzio, A., Bonfà, A., Hubl, W., Demant, T., Külpmann, W.-R., et al. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.077 · Cited by 83
Schüetz, P., Affolter, B., Hunziker, S., Winterhalder, C., Fischer, M., Balestra, G. M., Hunziker, P., & Marsch, S. C. U. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02259.x · Cited by 82
Mongardon, N., Lemiale, V., Perbet, S., Dumas, F., Legriel, S., Guérin, S., Charpentier, J., Chiche, J., Mira, J. P., & Cariou, A. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1681-3 · Cited by 66
Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis
Novotny, A., Emmanuel, K., Hueser, N., Knebel, C., Kriner, M., Ulm, K., Bartels, H., Siewert, J. R., & Holzmann, B. (2008) · Surgery · doi:10.1016/j.surg.2008.08.009 · Cited by 61
Inhibition of the renal excretion of tazobactam by piperacillin
Komuro, M., Maeda, T., Kakuo, H., Matsushita, H., & Shimada, J. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.4.555 · Cited by 46
Meisner, M., Hüttemann, E., Lohs, T., Kasakov, L., & Reinhart, K. (2001) · Shock · doi:10.1097/00024382-200115030-00002 · Cited by 40
Inhibition of flucloxacillin tubular renal secretion by piperacillin
Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig, M., Bulitta, J. B., Holzgrabe, U., & Sörgel, F. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03266.x · Cited by 37
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000298158.12101.41 · Cited by 9
Saitoh, H., Oda, M., Gyotoku, T., Kobayashi, M., Fujisaki, H., & Sekikawa, H. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.2519 · Cited by 9
Cited by
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Metadata
- Authors
- Jensen, J. U., Hein, L., Lundgren, B., Bestle, M. H., Mohr, T. T., Andersen, M. H., Thornberg, K. J., Løken, J., Steensen, M., Fox, Z., Tousi, H., Søe-Jensen, P., Lauritsen, A. Ø., Strange, D., Petersen, P. L., Reiter, N., Hestad, S., Thormar, K., Fjeldborg, P., Larsen, K. M., Drenck, N. E., Østergaard, C., Kjær, J., Grarup, J., & Lundgren, J. D.
- Affiliations
- University of Copenhagen (DK)
- ORCID
- Venue
- Critical Care Medicine
- Published
- 2011-09
- Volume
- 39
- Issue
- 9
- Pages
- 2048-2058
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2010751662
- Cited by
- 356
- References
- 39
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 17 · 2022: 11 · 2021: 21 · 2020: 19 · 2019: 30 · 2018: 25 · 2017: 33 · 2016: 28 · 2015: 27 · 2014: 31 · 2013: 43 · 2012: 35
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- procalcitonin, antimicrobial stewardship, antibiotic escalation, sepsis, critically ill patients, intensive care unit, 28-day mortality, length of hospital stay, mechanical ventilation, acute kidney injury, biomarker-guided therapy
- MeSH terms
- Aged, Algorithms, Anti-Bacterial Agents, Calcitonin, Female, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, Protein Precursors, Respiration, Artificial, Time Factors, Biomarkers, Calcitonin Gene-Related Peptide, Hospital Mortality, Sepsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.